SRCIN1 Suppressed Osteosarcoma Cell Proliferation and Invasion

Peng Wang1, Hu Wang2, Xiaotao Li3, Ying Liu4, Chengbin Zhao1*, Daling Zhu5,6*

1 Department of Orthopedics, The Fourth Hospital of Harbin Medical University, Harbin, Heilongjiang, 150001, China, 2 Department of Orthopedics, First Affiliated Hospital of Shantou University Medical College, Shantou, 515041, Guangdong Province, China, 3 Department of Orthopedics, The First Affiliated Hospital of Jiamusi University, Jiamusi, Heilongjiang, 154000, China, 4 Clinical medicine Grade Four, Harbin Medical University, Harbin, Heilongjiang, 150001, China, 5 Department of Biopharmaceutical Sciences, College of Pharmacy, Harbin Medical University Daqing, Daqing, 163319, China, 6 Biopharmaceutical Key Laboratory of Heilongjiang Province, Harbin, 150081, China

* chengbinzhao1@163.com (CZ); dalingz@yahoo.com (DZ)

Abstract

SRCIN1 (SRC kinase signalling inhibitor 1) is a new tumor suppressor gene. Previous studies showed that SRCIN1 played a tumor suppressor role in the development of lung cancer and breast cancer. However, the role of SRCIN1 in osteosarcoma is still unknown. In this study, we demonstrated that SRCIN1 was downregulated in osteosarcoma cell lines compared with osteoblastic cell line. Moreover, SRCIN1 was downregulated in osteosarcoma tissues compared with the adjacent tissues. Further investigation revealed that overexpression of SRCIN1 inhibited the osteosarcoma cell line MG-63 proliferation. This effect was confirmed by measuring the ki-67 and PCNA expression. SRCIN1 overexpression promoted E-cadherin expression and suppressed N-cadherin, Vimentin and Snail expression, suggesting that SRCIN1 overexpression inhibited EMT of the osteosarcoma cell. In addition, ectopic expression of SRCIN1 inhibited the MG-63 cell colony formation and invasion. These data suggested that SRCIN1 acted as a tumor suppressor gene in the development of osteosarcoma.

Introduction

Osteosarcoma is one of the most common primary bone malignancies in young adults and adolescents, with an estimated 5.6 per million children suffering from osteosarcoma yearly[1–4]. It occurs mostly in long extremity bone and around regions with active bone growth[5–8]. Despite the advances in treatment strategies of osteosarcoma, the 5-year survival rate of osteosarcoma patients is still poor[3, 9–12]. Thus, it is important to find the molecular mechanisms underlying the development of osteosarcoma and to identify novel biomarkers for the treatment, diagnosis and prognosis of this tumor[13–16].

SRCIN1 (SRC kinase signalling inhibitor 1), also named as p140 Cas-associated protein (p140CAP), contains two regions of highly charged amino acids, two proline-rich regions and two coiled-coil domains[17–20]. Previous studies demonstrated that SRCIN1 played an
important role in Src inactivation and acted as a tumor suppressor gene in cancers[18, 21]. For example, Cao et al[22], demonstrated that miR-150 acted as an oncogene through repressing SRCIN1 translation in lung cancer. Sharma et al[23], showed that SRCIN1 inhibited tumor growth and impaired invasive properties of cancer cells by regulating the tyrosine kinase Src or E-cadherin/EGFR signaling pathways. In addition, the expression of SRCIN1 was inversely correlated with tumor malignancy in breast cancer. Damiano et al[18], showed that SRCIN1 inhibited the highly metastatic breast carcinoma cells invasion by repressing cortactin-dependent cell motility. However, the role of SRCIN1 in osteosarcoma is still unknown.

In our study, we demonstrated that SRCIN1 was downregulated in the osteosarcoma cell lines and tissues. Overexpression of SRCIN1 inhibited the osteosarcoma cell proliferation and EMT. In addition, ectopic expression of SRCIN1 inhibited the MG-63 cell colony formation and invasion.

**Materials and Methods**

**Clinical specimens and cell line cultured and transfection**

Thirty osteosarcoma and adjacent nontumor bone tissues were collected from patients who underwent surgery in our hospital. Samples were immediately snap-frozen in liquid nitrogen. All of the patients have written informed consent to participate in this study. This study was approved by the Ethics Committee of The Fourth Hospital of Harbin Medical University and complied with the Declaration of Helsinki. Human osteosarcoma cell lines (U2OS, MG63, SAOS-2 and SOSP-9607) and one osteoblastic cell line (hFOB) were obtained from the ATCC (American Tissue Culture Collection). Lipofectamine 2000 (Dharmacon, TX, USA) was used to perform to cell transfection.

**RNA extraction and qRT-PCR**

Total RNA from tissues and cells were isolated by using Trizol reagent (Invitrogen, Calsbad, CA, USA). Relative expression levels of SRCIN1 mRNA were measured by real-time PCR on the iQ5 Real-Time PCR Detection System (Bio-Rad, California, USA). Quantitative PCR primer for SRCIN1 was forward: 5’ –AGCCCCGACAAAAAGCAAC–3’ and reverse: 5’ – CCAAGGGAAGTCAATACAGGGATAG–3’; GAPDH was forward: 5’ –AATGGGCAGCCGTTAGGAAA–3’ and reverse: 5’ –TGAAGGGGTACATTGATGGCA–3’. GAPDH was used to as an endogenous control.

**Cell proliferation and colony formation**

Cell Counting Kit-8 (CCK-8)(Dojindo; Kumamoto, Japan) was performed to measure the cell proliferation. Cells were cultured in 96-well plates for 1, 2or 3 days. The absorbance was detected at a wave length of 450 nm. For cell colony analysis, the cells were cultured at 1000cells/plate density and continue to seed for 2 weeks.

**Cell invasion**

For cell invasion analysis, cells were seeded on the top side of transwell chambers coated with Matrigel (BD Bioscience). Mediumin the lower chambers containing 10% FBS acted as the chemo-attractant. After 24 h, the cells moving to the lower side of the membrane were fixed, stained with crystal violet and then counted by a microscope (BX51 Olympus, Japan).
Western blot

Western blot analysis was measured according to previous studies. Proteins were isolated and detected using the BCA kit (Thermo Scientific, Rockford, IL). Proteins were separated by 10% SDS-PAGE and then transferred to PVDF membranes (Millipore, Danvers, MA). Membranes were cultured with primary antibodies GAPDH (Santa Cruz, CA) or SRCIN1 (Cell Signaling Technology). GAPDH was used as a loading control.

Statistical analysis

Data was shown as means±SD. Statistics was measured using ANOVA or Student’s t-test using SPSS17.0. Statistical significance was shown as P<0.05.

Results

SRCIN1 was downregulated in the osteosarcoma cells

One representative patient was diagnosed as osteosarcoma using HE staining (Fig 1A). The mRNA expression of SRCIN1 was lower in the osteosarcoma cell lines (MG63, U2OS, SAOS-2 and HOS) than in the one osteoblastic cell line (hFOB) (Fig 1B). In line with this, the protein expression of SRCIN1 was lower in the osteosarcoma cell lines (MG63, U2OS, SAOS-2 and HOS) than in hFOB (Fig 1C).

SRCIN1 expression was reduced in the osteosarcoma tissues

SRCIN1 expression was also lower in the osteosarcoma tissues than in the adjacent nontumor tissues (Fig 2A). Meanwhile, SRCIN1 expression was downregulated in 29 patients (29/35, 82%) compared with the adjacent tissues. We also confirmed that the protein expression of SRCIN1 was downregulated in the osteosarcoma tissues (Fig 2C).

SRCIN1 suppressed the osteosarcoma cell proliferation

As shown in Fig 3A and 3B, SRCIN1 expression was increased after transfected with SRCIN1 vector. Overexpression of SRCIN1 suppressed cell proliferation in the osteosarcoma cell line MG63 (Fig 3C). As shown in Fig 3D and 3E, the expression of ki-67 was decreased after

Fig 1. The expression of SRCIN1 was downregulated in the osteosarcoma cells. (A) One representative patient was diagnosed as osteosarcoma using HE staining. (B) The mRNA expression of SRCIN1 was measured by using qRT-PCR. (C) The protein expression of SRCIN1 was measured by using western blot.

doi:10.1371/journal.pone.0155518.g001
transfected with SRCIN1 vector. Overexpression of SRCIN1 inhibited the PCNA expression in the MG-63 cell (Fig 3F and 3G).

SRCIN1 inhibited epithelial–mesenchymal transition of the osteosarcoma cell

Overexpression of SRCIN1 enhanced E-cadherin mRNA expression while suppressed N-cadherin, Vimentin and Snail mRNA expression (Fig 4A). Moreover, we also showed that SRCIN1 overexpression promoted the expression of E-cadherin and inhibited the expression of N-cadherin, Vimentin and Snail (Fig 4B).

SRCIN1 repressed the osteosarcoma cell colony formation and invasion

Ectopic expression of SRCIN1 inhibited the MG-63 cell colony formation (Fig 5A). Moreover, overexpression of SRCIN1 suppressed the MG-63 cell invasion (Fig 5B).

Discussion

In this study, we demonstrated that SRCIN1 was downregulated in the osteosarcoma cell lines compared with osteoblastic cell line. Moreover, we showed that SRCIN1 expression was downregulated in osteosarcoma tissues compared with the adjacent tissues. Overexpression of SRCIN1 inhibited the osteosarcoma cell line MG63 proliferation. Furthermore, this effect was confirmed by measuring the ki-67 and PCNA expression. SRCIN1 overexpression promoted E-cadherin expression and suppressed N-cadherin, Vimentin and Snail expression. This result suggested that SRCIN1 overexpression inhibited EMT of the osteosarcoma cell. In
addition, ectopic expression of SRCIN1 inhibited the MG-63 cell colony formation and invasion. These data suggested that SRCIN1 acts as a tumor suppressor gene in the development of osteosarcoma.

Previous studies showed that SRCIN1 acted as a crucial role in Src inactivation and acted as a tumor suppressor gene in a lot of tumors [18–21]. For example, Cao et al. [22] showed that miR-150 acted as an oncogene by inhibiting SRCIN1 translation in lung cancer. Sharma et al. [23] demonstrated that SRCIN1 suppressed tumor growth and impaired invasive properties of cancer cells through inhibiting the tyrosine kinase Src or E-cadherin/EGFR signaling pathways. Moreover, the expression of SRCIN1 was inversely associated with tumor malignancy in breast cancer. Damiano et al. [18] demonstrated that SRCIN1 suppressed the highly metastatic breast
carcinoma cells invasion by inhibiting cortactin-dependent cell motility. However, the role of SRCIN1 in osteosarcoma is still uncovered. In this study, we showed that SRCIN1 was downregulated in the osteosarcoma cell lines compared with osteoblastic cell line. Furthermore, we measured the SRCIN1 expression in 35 osteosarcoma patients’ tissues. We demonstrated that the expression of SRCIN1 was lower in the osteosarcoma tissues than in the adjacent non-tumor tissues. Meanwhile, SRCIN1 was downregulated in 29 patients (29/35, 82%) compared with the adjacent tissues.

Fig 4. SRCIN1 inhibited epithelial–mesenchymal transition of the osteosarcoma cell. (A) The mRNA expression of E-cadherin, N-cadherin, Vimentin and Snail was measured by using qRT-PCR in the MG-63 cells after treated SRCIN1 vector. (B) The protein expression of E-cadherin, N-cadherin, Vimentin and Snail was detected by using western blot in the MG-63 cells after treated SRCIN1 vector.

doi:10.1371/journal.pone.0155518.g004

Fig 5. SRCIN1 repressed the osteosarcoma cell colony formation and invasion. (A) Ectopic expression of SRCIN1 inhibited the MG-63 cell colony formation. (B) Overexpression of SRCIN1 suppressed the MG-63 cell invasion. ***p<0.001.

doi:10.1371/journal.pone.0155518.g005
We further investigated the role of SRCIN1 in osteosarcoma cell. Overexpression of SRCIN1 inhibited the osteosarcoma cell line MG63 proliferation. This effect was further confirmed by measuring the ki-67 and PCNA expression. SRCIN1 overexpression promoted the expression of E-cadherin while it suppressed N-cadherin, Vimentin and Snail expression. This result suggested that SRCIN1 overexpression inhibited EMT of the osteosarcoma cell. In addition, ectopic expression of SRCIN1 suppressed the MG-63 cell colony formation and invasion. These data suggested that SRCIN1 acted as a tumor suppressor gene in the development of osteosarcoma.

In conclusion, SRCIN1 may serve as a tumor suppressor gene in the development and metastasis of osteosarcoma. Given that ectopic expression of SRCIN1 suppresses cell proliferation and metastasis in the osteosarcoma, SRCIN1 may be a potent marker for the development of therapeutic strategies for patients with osteosarcoma.

**Author Contributions**

Conceived and designed the experiments: PW HW XL CZ DZ.

Performed the experiments: PW HW XL YL CZ DZ.

Analyzed the data: PW HW XL CZ DZ.

Contributed reagents/materials/analysis tools: PW HW XL CZ DZ.

Wrote the paper: PW HW XL CZ DZ.

**References**

1. Tang J, Shen L, Yang Q, Zhang C. Overexpression of metadherin mediates metastasis of osteosarcoma by regulating epithelial-mesenchymal transition. Cell proliferation. 2014; 47(5):427–34. Epub 2014/09/02. doi:10.1111/cpr.12129 PMID: 25174891.

2. Niu G, Li B, Sun J, Sun L. miR-454 is down-regulated in osteosarcomas and suppresses cell proliferation and invasion by directly targeting c-Met. Cell proliferation. 2015; 48(3):348–55. Epub 2015/04/17. doi: 10.1111/cpr.12187 PMID: 25880599.

3. van der Deen M, Taipaleenmaki H, Zhang Y, Teplyuk NM, Gupta A, Cinghu S, et al. MicroRNA-34c Inversely Couples the Biological Functions of the Runt-related Transcription Factor RUNX2 and the Tumor Suppressor p53 in Osteosarcoma. The Journal of biological chemistry. 2013; 288(29):21307–19. Epub 2013/05/31. doi: 10.1074/jbc.M112.445890 PMID: 23720736.

4. Geng S, Zhang X, Chen J, Liu X, Zhang H, Xu X, et al. The tumor suppressor role of miR-124 in osteosarcoma. PloS one. 2014; 9(6):e91566. Epub 2014/06/28. doi: 10.1371/journal.pone.0091566 PMID: 24971902; PubMed Central PMCID: PMC4074038.

5. Zhang C, Yao C, Li H, Wang G, He X. Combined elevation of microRNA-196a and microRNA-196b in sera predicts unfavorable prognosis in patients with osteosarcomas. International journal of molecular sciences. 2014; 15(4):6544–55. Epub 2014/04/22. doi: 10.3390/ijms15046544 PMID: 24747591; PubMed Central PMCID: PMC4013646.

6. Hong Q, Fang J, Pang Y, Zheng J. Prognostic value of the microRNA-29 family in patients with primary osteosarcomas. Med Oncol. 2014; 31(8):37. Epub 2014/07/13. doi: 10.1007/s12032-014-0037-1 PMID: 25015394.

7. Lv H, Pei J, Liu H, Wang H, Liu J. A polymorphism site in the premiR34a coding region reduces miR34a expression and promotes osteosarcoma cell proliferation and migration. Molecular medicine reports. 2014; 10(6):2912–6. Epub 2014/09/23. doi: 10.3892/mmr.2014.2582 PMID: 25242229; PubMed Central PMCID: PMC4227432.

8. Zhang C, Yao C, Li H, Wang G, He X. Serum levels of microRNA-133b and microRNA-206 expression predict prognosis in patients with osteosarcoma. International journal of clinical and experimental pathology. 2014; 7(7):4194–203. Epub 2014/08/15. PMID: 25120799; PubMed Central PMCID: PMC4129034.

9. Gao Y, Luo LH, Li S, Yang C. miR-17 inhibitor suppressed osteosarcoma tumor growth and metastasis via increasing PTEN expression. Biochemical and biophysical research communications. 2014; 444(2):230–4. Epub 2014/01/28. doi: 10.1016/j.bbrc.2014.01.061 PMID: 24462867.
10. Wang L, Shao J, Zhang X, Xu M, Zhao J. microRNA-377 suppresses the proliferation of human osteosarcoma MG-63 cells by targeting CDK6. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2015. Epub 2015/01/13. doi: 10.1007/s13277-014-3034-2 PMID: 25577249.

11. Niu G, Li B, Sun L, An C. MicroRNA-153 Inhibits Osteosarcoma Cells Proliferation and Invasion by Targeting TGF-beta2. PLoS one. 2015; 10(3):e0119225. Epub 2015/03/21. doi: 10.1371/journal.pone.0119225 PMID: 25793604; PubMed Central PMCID: PMC4368543.

12. Wang XH, Cai P, Wang MH, Wang Z. microRNA25 promotes osteosarcoma cell proliferation by targeting the cellcycle inhibitor p27. Molecular medicine reports. 2014; 10(2):855–9. Epub 2014/05/27. doi: 10.3892/mmr.2014.2260 PMID: 24859599.

13. Zhang J, Yan YG, Wang C, Zhang SJ, Yu XH, Wang WJ. MicroRNAs in osteosarcoma. Clinica chimica acta; international journal of clinical chemistry. 2015; 444:9–17. Epub 2015/02/11. doi: 10.1016/j.cca.2015.01.025 PMID: 25661090.

14. Wang G, Li B, Fu Y, He M, Wang J, Shen P, et al. miR-23a suppresses proliferation of osteosarcoma cells by targeting SATB1. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2015. Epub 2015/01/27. doi: 10.1007/s13277-015-3120-0 PMID: 25619478.

15. Iwasaki T, Tanaka K, Kawano M, Itonaga I, Tsumura H. Tumor-suppressive microRNA-let-7a inhibits cell proliferation via targeting of E2F2 in osteosarcoma cells. International journal of oncology. 2015; 46(4):1543–50. Epub 2015/02/04. doi: 10.3892/ijo.2015.2867 PMID: 25647078.

16. Miao J, Wu S, Peng Z, Tania M, Zhang C. MicroRNAs in osteosarcoma: diagnostic and therapeutic aspects. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013. Epub 2013/06/26. doi: 10.1007/s13277-013-0940-7 PMID: 23797816.

17. Di Stefano P, Leal MP, Tomillo G, Bisaro B, Repetto D, Pincini A, et al. The adaptor proteins p140Cap and p130CAS as molecular hubs in cell migration and invasion of cancer cells. American journal of cancer research. 2011; 1(5):663–73. Epub 2011/10/14. PMID: 21994904; PubMed Central PMCID: PMC3189826.

18. Damiano L, Le Devedec SE, Di Stefano P, Repetto D, Lalai R, Truong H, et al. p140Cap suppresses the invasive properties of highly metastatic MTLn3-EGFR cells via impaired cortactin phosphorylation. Oncogene. 2012; 31(8):624–33. Epub 2011/07/05. doi: 10.1038/onc.2011.257 PMID: 21725361.

19. Damiano L, Di Stefano P, Camacho Leal MP, Barba M, Mainiero F, Cabodi S, et al. p140Cap dual regulation of E-cadherin/EGFR cross-talk and Ras signalling in tumour cell scatter and proliferation. Oncogene. 2010; 29(25):3677–90. Epub 2010/05/11. doi: 10.1038/onc.2010.128 PMID: 20453866.

20. Di Stefano P, Damiano L, Cabodi S, Aramu S, Tordella L, Praduroux A, et al. p140Cap protein suppresses tumour cell properties, regulating Csk and Src kinase activity. The EMBO journal. 2007; 26(12):2843–55. Epub 2007/05/26. doi: 10.1038/sj.emboj.7601724 PMID: 17525734; PubMed Central PMCID: PMC1884765.

21. Kennedy S, Clynes M, Doolan P, Mehta JP, Rani S, Crown J, et al. SNIP/p140Cap mRNA expression is an unfavourable prognostic factor in breast cancer and is not expressed in normal breast tissue. British journal of cancer. 2008; 98(10):1641–5. Epub 2008/05/14. doi: 10.1038/sj.bjc.6604365 PMID: 18475297; PubMed Central PMCID: PMC2391132.

22. Cao M, Hou D, Liang H, Gong F, Wang Y, Yan X, et al. miR-150 promotes the proliferation and migration of lung cancer cells by targeting SRC kinase signalling inhibitor 1. Eur J Cancer. 2014; 50(5):1013–24. Epub 2014/01/25. doi: 10.1016/j.ejca.2013.12.024 PMID: 24456795.

23. Sharma N, Repetto D, Aramu S, Grasso S, Russo I, Fiorentino A, et al. Identification of two regions in the p140Cap adaptor protein that retain the ability to suppress tumor cell properties. American journal of cancer research. 2013; 3(3):290–301. Epub 2013/07/11. PMID: 23841028; PubMed Central PMCID: PMC3696535.